A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer

Trial Profile

A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms RAPTOR
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 24 Sep 2016 Results of final analysis published in the European Journal of Cancer.
    • 16 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrial.gov record.
    • 08 May 2014 Planned End Date changed from 1 Feb 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top